On this page
COL3A1
collagen type III alpha 1 chain
The COL3A1 gene provides instructions for making type III collagen, a crucial component of connective tissues, playing a vital role in the integrity of blood vessels, skin, and internal organs. The COL3A1 gene encodes for the alpha-1 chain of type III collagen, a key structural protein that contributes to the strength and elasticity of various tissues throughout the body.
COL3A1 is located on the long (q) arm of chromosome 2, at band 2q32.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 2 in the library →Overview
The COL3A1 gene, also known as collagen type III alpha 1 chain, is fundamental for the production of type III collagen. This protein is a major constituent of connective tissues, which provide structural support and strength to many parts of the body, including the skin, lungs, intestinal walls, and the walls of blood vessels. Understanding the COL3A1 gene's function is important for comprehending the basis of certain inherited connective tissue disorders.
Type III collagen is particularly abundant in distensible tissues that require both strength and flexibility. The integrity of these tissues relies heavily on properly formed type III collagen. Alterations in the COL3A1 gene can disrupt the normal production or structure of this collagen, leading to conditions that affect these vital bodily systems. The study of COL3A1 contributes to our knowledge of extracellular matrix biology and genetic predispositions to specific health concerns.
What the gene does
The COL3A1 gene directs the synthesis of the pro-alpha 1(III) chain, which is a fundamental building block of type III collagen. Type III collagen is part of a larger family of proteins known as collagens, whose primary role is to provide structural support and mechanical strength to various tissues within the body. Specifically, type III collagen is found in high concentrations in tissues that require significant elasticity and strength, such as the skin, the walls of blood vessels, and the intestines.
The process of forming mature type III collagen begins with the production of three pro-alpha 1(III) chains. These chains then assemble into a triple-stranded, rope-like structure called a procollagen molecule. Following their synthesis, these procollagen molecules are secreted from the cell and undergo further processing by enzymes in the extracellular space. This enzymatic cleavage removes certain regions, allowing the molecules to become mature type III collagen.
Once mature, the collagen molecules spontaneously organise into long, thin structures known as fibrils. These fibrils are further stabilised through the formation of robust cross-links, not only among themselves but also with other types of collagen in the spaces between cells. This intricate assembly and cross-linking result in the formation of very strong and resilient collagen fibres, which are essential for maintaining the structural integrity and elasticity of connective tissues throughout the body.
Video: Genetics 101
Chromosome location
The COL3A1 gene is situated on chromosome 2, specifically at position 2q32.2. This chromosomal location indicates its precise address within the human genome. The gene spans a considerable length of DNA, containing instructions for assembling the type III collagen alpha-1 chain. Its position is consistently identified across individuals, allowing for genetic mapping and the investigation of its role in health and disease.
Protein structure
The COL3A1 protein, known as collagen type III alpha 1 chain, has a total length of 1466 amino acids. Its structural organisation includes several distinct domains and regions that are crucial for its function in forming type III collagen fibres. At the N-terminal end, it features a VWFC domain, spanning amino acids 30-89, which is associated with von Willebrand factor C domains. Following this, a large Disordered region is present, extending from amino acids 95-1194, indicating a segment that may lack a fixed three-dimensional structure under physiological conditions but can adopt specific conformations upon binding to other molecules.
Within this larger region, there are two distinct Nonhelical regions: one at the N-terminus from amino acids 149-167, and another at the C-terminus from amino acids 1197-1205. These nonhelical segments flank the central Triple-helical region, which is a defining characteristic of collagen proteins, spanning amino acids 168-1196. This triple-helical structure is essential for the protein's assembly into collagen fibrils. Finally, the protein concludes with a Fibrillar collagen NC1 domain, located at amino acids 1232-1466, which is involved in the C-terminal assembly of collagen molecules and regulates fibril formation.
Key variants
Variants within the COL3A1 gene encompass a range of genetic alterations that can impact the production or function of type III collagen. These changes can include single nucleotide variations, small insertions or deletions, and larger genomic rearrangements. The consequences of these variants depend on their specific nature and location within the gene, potentially affecting the stability, assembly, or interaction of the collagen protein.
Many identified COL3A1 variants are associated with inherited connective tissue disorders, primarily affecting the integrity of blood vessels, skin, and internal organs. The impact of a specific variant can vary, from subtle effects on collagen structure to severe disruptions that lead to significant health complications. Genetic testing can identify COL3A1 variants, providing valuable information for diagnosis and risk assessment within affected families.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.3257_3266delGTCCTCAAGG | - | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.1024G>A | p.Gly342Arg | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.1052G>T | p.Gly351Val | Pathogenic/Likely pathogenic | ★★☆☆ | Ehlers-Danlos syndrome, type 4 |
c.105dup | p.Gly36fs | Pathogenic | ★★☆☆ | Familial thoracic aortic aneurysm and aortic dissection |
c.1079G>A | p.Gly360Asp | Pathogenic/Likely pathogenic | ★★☆☆ | Familial thoracic aortic aneurysm and aortic dissection |
c.1178G>T | p.Gly393Val | Pathogenic/Likely pathogenic | ★★☆☆ | Ehlers-Danlos syndrome, type 4 |
c.1258G>A | p.Gly420Ser | Pathogenic/Likely pathogenic | ★★☆☆ | Ehlers-Danlos syndrome, type 4 |
c.1267G>A | p.Gly423Ser | Pathogenic/Likely pathogenic | ★★☆☆ | Ehlers-Danlos syndrome, type 4 |
c.1282C>T | p.Arg428Ter | Pathogenic | ★★☆☆ | Polymicrogyria with or without vascular-type Ehlers-Danlos syndrome |
c.1294-1G>A | - | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the COL3A1 gene are principally linked to Vascular Ehlers-Danlos syndrome (AD). This is an inherited connective tissue disorder characterised by extreme fragility of blood vessels and internal organs, making individuals susceptible to life-threatening complications such as arterial rupture, bowel perforation, or uterine rupture during pregnancy. The condition typically presents with thin, translucent skin, easy bruising, and characteristic facial features, but the most serious concerns relate to internal organ and blood vessel vulnerability. Understanding the genetic basis through COL3A1 analysis is crucial for accurate diagnosis and management of this condition.
Inheritance pattern
Conditions caused by pathogenic COL3A1 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
In the UK, the COL3A1 gene is recognised within the NHS Genomic Medicine Service (GMS) pathways, indicating its clinical significance for diagnostic testing. It is currently included in several accredited gene panels listed on PanelApp. These include panels for "Bleeding and platelet disorders," "Cerebral vascular malformations," "Ehlers Danlos syndrome with a likely monogenic cause," "Familial cerebral small vessel disease," "Foetal anomalies," "Malformations of cortical development," "Pneumothorax - familial," "Thoracic aortic aneurysm or dissection," and "Thoracic aortic aneurysm or dissection (GMS)". The "green" status for these panels signifies that there is sufficient evidence for routine use in diagnostic testing within the NHS.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with COL3A1-related conditions, particularly Vascular Ehlers-Danlos syndrome, lifestyle modifications are generally focused on reducing the risk of trauma and strain on blood vessels and internal organs. While specific lifestyle interventions cannot alter the genetic basis of the condition, certain precautions may help in managing symptoms and preventing complications. Research suggests that avoiding activities that involve high impact, heavy lifting, or significant physical exertion may be beneficial, as these can increase the risk of arterial dissection or rupture. Similarly, engaging in gentle, low-impact exercises may help maintain overall physical fitness without placing undue stress on fragile tissues.
Maintaining a healthy diet and managing blood pressure are also often recommended for general cardiovascular health, which may be particularly relevant for individuals with vascular fragility. However, these are general health recommendations, and any specific lifestyle advice for individuals with COL3A1-related conditions should come from a healthcare professional, considering their unique clinical presentation and risk profile.
Supplement considerations
There is no conclusive scientific evidence to suggest that specific dietary supplements can prevent, treat, or cure COL3A1-related conditions, such as Vascular Ehlers-Danlos syndrome. While some individuals may consider supplements like vitamin C or collagen peptides due to their perceived role in connective tissue health, there is no robust clinical data demonstrating their efficacy or safety in individuals with genetic collagen disorders. The structural defects caused by COL3A1 variants are typically fundamental to protein production or assembly, which supplements are unlikely to address.
Before considering any dietary supplements, individuals should always consult with a qualified healthcare professional. This is particularly important for those with COL3A1-related conditions, as certain supplements could potentially interact with medications or have unforeseen effects on a compromised vascular system. A healthcare provider can offer personalised advice based on an individual's specific health needs and clinical picture.
Frequently asked questions
What is the primary function of the COL3A1 gene?
The COL3A1 gene provides instructions for creating the alpha-1 chain of type III collagen, a crucial structural protein that gives strength and elasticity to connective tissues found in blood vessels, skin, and internal organs.
Which condition is most commonly associated with COL3A1 variants?
Pathogenic variants in the COL3A1 gene are predominantly associated with Vascular Ehlers-Danlos syndrome, a genetic disorder characterised by fragile blood vessels and other connective tissue abnormalities.
Is Vascular Ehlers-Danlos syndrome inherited?
Yes, Vascular Ehlers-Danlos syndrome associated with COL3A1 variants is typically inherited in an autosomal dominant pattern, meaning only one copy of the altered gene in each cell is sufficient to cause the condition.
Where is the COL3A1 gene located?
The COL3A1 gene is located on chromosome 2, specifically at position 2q32.2 in the human genome.
Does COL3A1 appear on NHS genetic testing panels?
Yes, COL3A1 is included in several NHS Genomic Medicine Service (GMS) panels, such as those for Ehlers-Danlos syndrome, thoracic aortic aneurysm or dissection, and cerebral vascular malformations, indicating its relevance for clinical diagnosis in the UK.
Can lifestyle changes or supplements help with COL3A1-related conditions?
While lifestyle adjustments may help manage general health and reduce physical strain, there is no conclusive evidence that specific lifestyle changes or dietary supplements can prevent or treat COL3A1-related conditions. Any such interventions should be discussed with a healthcare professional.
References
- Malfait F, Francomano C, Byers P. The 2017 international classification of the Ehlers-Danlos syndromes. American journal of medical genetics. Part C, Seminars in medical genetics. 2017. PMID: 28306229
- Beridze N, Frishman WH. Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications. Cardiology in review. 2012. PMID: 22143279
- Germain DP. Ehlers-Danlos syndrome type IV. Orphanet journal of rare diseases. 2007. PMID: 17640391
- Oderich GS, Panneton JM, Bower TC. The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. Journal of vascular surgery. 2005. PMID: 16012458
- Schwarze U, Schievink WI, Petty E. Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. American journal of human genetics. 2001. PMID: 11577371
- Giunta C, Steinmann B. Characterization of 11 new mutations in COL3A1 of individuals with Ehlers-Danlos syndrome type IV: preliminary comparison of RNase cleavage, EMC and DHPLC assays. Human mutation. 2000. PMID: 10923041